TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02623153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: oxaliplatin 130 mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: oxaliplatin 130 mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: capecitabine of 1000 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: S1 of 40 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: docetaxel 40 mg/m2
Study: NCT04579627

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: A single survey questionnaire to staff to report their demographics and facial hair styles between January and April 2020
Study: NCT00912691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM-AT
Description: Single unit dose powder of active substance (CM-AT) administered 3 times per day for 90 days
Study: NCT00512460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTA 744
Description: 4.8 mg/m\^2 by vein Over 2 Hours On Days 1-3.
Study: NCT01055379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasagiline
Description: 1 mg/day for 12 weeks; orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily for 12 weeks; orally
Study: NCT00697879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHR-3996
Description: Once daily oral ingestion of capsules (5, 10, 20 or 40 mg), dose depending on cohort, treatment cycle of 28 days
Study: NCT00639353

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A toric soft contact lens
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A sphere soft contact lens
Description: contact lens
Study: NCT00610467

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Disease Group
Description: Participants will received the following agents before their imaging are taken MRI contrast agent (0.1 mmol/kg) optical contrast agent ICG (0.5 mg/kg)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control Group
Description: Participants will received the following agents before their imaging are taken MRI contrast agent (0.1 mmol/kg) optical contrast agent ICG (0.5 mg/kg)
Study: NCT02697292

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Immunoglobulin
Description: GAMUNEX-C is a clear a ready-to-use sterile solution of human immune globulin protein for intravenous administration. Dose will be determined based on ideal wt. with not to exceed 80 grams. Subjects will receive 0.5g/kg daily for 1 day \[week 1 day 1\], then will receive 1g/kg not exceeding 80 grams daily for 1 day \[week 1 day 2\]. Then once every 2 weeks subjects will receive 0.6g/kg IVIG for 4 weeks \[week 3 and 5\] for 2 infusions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Immunoglobulin
Description: GAMUNEX-C is a clear a ready-to-use sterile solution of human immune globulin protein for intravenous administration. Dose will be determined based on ideal wt. with not to exceed 80 grams. Subjects will receive 0.5g/kg daily for 1 day \[week 1 day 1\], then will receive 1g/kg not exceeding 80 grams daily for 1 day \[week 1 day 2\]. Then once every 2 weeks subjects will receive 0.6g/kg IVIG for 4 weeks \[week 3 and 5\] for 2 infusions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Normal Saline is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. Dose will be determined based on ideal wt. with not to exceed 80 grams. Dose will be determined based on ideal wt. with not to exceed 80 grams. Subjects will receive 0.5g/kg daily for 1 day \[week 1 day 1\], then will receive 1g/kg not exceeding 80 grams daily for 1 day \[week 1 day 2\]. Then once every 2 weeks subjects will receive 0.6g/kg for 4 weeks \[week 3 and 5\] for 2 infusions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. Subjects will receive 500 ml normal saline before and after the higher dose infusion of 1g/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. Subjects will receive 500 ml normal saline before and after the higher dose infusion of 1g/kg
Study: NCT02094755

Intervention type: OTHER
Intervention: Blood draw only
Description: Blood draw only
Study: NCT01251731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5501
Description: Treatment Group 1: 10mg E5501 as a single dose in Treatment Period 1, followed by a single dose of 40mg E5501 in Treatment Period 2, followed by a single dose of 80mg E5501 in Treatment Period 3, followed by a selected dose for the Multiple Dose reatment Period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5501
Description: Treatment Group 2: 40 mg E5501 as a single dose in Treatment Period 1, followed by a single dose of 80mg E5501 in Treatment Period 2, followed by a single dose of 10mg E5501 in Treatment Period 3, followed by a selected dose for the Multiple Dose Treatment Period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5501
Description: Treatment Group 3: 80mg E5501 as a single dose in Treatment Period 1, followed by a single dose of 10mg E5501 in Treatment Period 2, followed by a single dose of 40mg E5501 in Treatment Period 3, followed by a selected dose for the Multiple Dose Treatment Period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E5501
Description: Treatment Group 4: A single dose of matching placebo in each of the three Single Dose Treatment Periods and in the Multiple Dose Treatment Period
Study: NCT04651075

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music listening
Description: The music selected by the participants was played to the music listening group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: individual training
Description: Individual training group was trained on coronary angiography.
Study: NCT01063660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan
Description: 14 g/m²/d day -6 to -4
Study: NCT03034629

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short-term aerobic exercise
Description: One bout of moderate intensity exercise (75% of maximal predicated heart rate).
Study: NCT03433248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMPA/LINA 10/5 mg QD (n=22)
Description: Once daily treatment with oral empagliflozin (Jardiance) 10 mg Once daily treatment with oral linagliptin (Tradjenta) 5 mg
Study: NCT03723642

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: VOC 45min
Description: Volatile organic compound sampling (2 samples within 5 minutes) 45 minutes after skin incision.
Study: NCT03433248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMPA/LINA 10/5 mg QD (n=22)
Description: Once daily treatment with oral empagliflozin (Jardiance) 10 mg Once daily treatment with oral linagliptin (Tradjenta) 5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LINA/EMPA 5/10 mg QD (N=22)
Description: Once daily treatment with oral linagliptin (Tradjenta) 5 mg Once daily treatment with oral empagliflozin (Jardiance) 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LINA/EMPA 5/10 mg QD (N=22)
Description: Once daily treatment with oral linagliptin (Tradjenta) 5 mg Once daily treatment with oral empagliflozin (Jardiance) 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gliclazide 30 mg QD/BID (N=22)
Description: Once daily or twice daily treatment with oral glicazide MR 30mg
Study: NCT03160651

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone or placebo
Description: Patients will receive 28 days of methylprednisolone 32 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone or placebo
Description: Patients will receive 28 days of methylprednisolone 32 mg/day
Study: NCT03723642

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Final VOC
Description: Volatile organic compound sampling (2 samples within 5 minutes) within 5 minutes after skin closure.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Final VOC
Description: Volatile organic compound sampling (2 samples within 5 minutes) within 5 minutes after skin closure.
Study: NCT04393454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus 2mg Tablet
Description: Sirolimus (oral) will be started at 2 mg daily. Sirolimus dosing will be titrated to meet serum trough levels of \>8 ng/ml, assayed at 7 days after starting a new dose, by chromatography/mass spectrometry. Once adequate serum levels are met (≥8 ng/ml), the same dosing will be continued until progression of disease as evidenced by imaging, or unacceptable toxicity.
Study: NCT02987712

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thromboelastography based protocol
Description: patients will be treated according to a new thromboelastography based protocol
Study: NCT01224145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5x5cm bupivacaine collagen sponges
Study: NCT02000206

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alfentanil
Study: NCT02119377

Intervention type: OTHER
Intervention: questionnaire
Study: NCT02211846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: oral
Study: NCT01334450

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS , H2-coil
Description: Trans cranial magnetic stimulation with H2-coil

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS , H2-coil
Description: Trans cranial magnetic stimulation with H2-coil

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TMS , H2-coil
Description: Trans cranial magnetic stimulation with H2-coil
Study: NCT01264796

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: culturally tailored diabetes education
Description: lifestyle modification group education
Study: NCT03843814

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: APT MRI
Study: NCT03690297

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Linked Color Imaging
Description: Use of narrow band imaging with LCI for colon inspection during both insertion and withdrawal phase of colonoscopy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Linked Color Imaging
Description: Use of narrow band imaging with LCI for colon inspection during both insertion and withdrawal phase of colonoscopy
Study: NCT04220307

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK104
Description: Subjects will receive AK104 by intravenous administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK104
Description: Subjects will receive AK104 by intravenous administration
Study: NCT03404193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT02835287

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protocol-based integrated care
Description: The protocol-based integrated care, which will provide a standardized, combined, multi-component intervention according to clinical guideline treatment algorithms for diabetes and comorbidities in community clinics, will be delivered by trained primary care physicians, health managers, and nurses supported by diabetes specialists.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocol-based integrated care
Description: The protocol-based integrated care, which will provide a standardized, combined, multi-component intervention according to clinical guideline treatment algorithms for diabetes and comorbidities in community clinics, will be delivered by trained primary care physicians, health managers, and nurses supported by diabetes specialists.
Study: NCT02315742

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Let's Move Program
Description: Patients will walk 5 times per week for 12 weeks for a minimum of 30 minutes while using a heart rate monitor. After the first two weeks of walking, patients will attend four consecutive group meetings which a research team member will look at walking logs and download data from heart rate monitor to focus on progress. Patient will receive weekly phone calls to monitor progress and to change walking duration or intensity level.
Study: NCT03736590

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Financial coaching and services
Description: The intervention will consist of clinic-based financial coaching that focuses on improving financial stability through longitudinal visits with financial services professionals to address financial goals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial coaching and services
Description: The intervention will consist of clinic-based financial coaching that focuses on improving financial stability through longitudinal visits with financial services professionals to address financial goals.
Study: NCT03626103

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: + Brief ED Intervention (BI)
Description: Brief ED Intervention (BI): A 20-minute Motivational Interviewing- and Cognitive Behavioral Therapy-based in-Emergency Department session delivered by a bachelors'-level Research Assistant

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: + Brief ED Intervention (BI)
Description: Brief ED Intervention (BI): A 20-minute Motivational Interviewing- and Cognitive Behavioral Therapy-based in-Emergency Department session delivered by a bachelors'-level Research Assistant

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: + Text
Description: Text: 8 weeks of an automated, tailored, two-way text-message curriculum started after the ED visit, which reinforces cognitive reappraisal, emotional regulation, and self-efficacy skills. Those that do not show improvement in mood after 7 days will be randomized into LiveText.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: + Text
Description: Text: 8 weeks of an automated, tailored, two-way text-message curriculum started after the ED visit, which reinforces cognitive reappraisal, emotional regulation, and self-efficacy skills. Those that do not show improvement in mood after 7 days will be randomized into LiveText.
Study: NCT02833233

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Study: NCT02293031

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gene-activated matrix Nucleostim
Description: Gene-activated matrix Nucleostim is bone graft substitute consisting of collagen-hydroxyapatite composite scaffold and DNA plasmids with gene encoding vascular endothelial grothw factor (VEGF-A165) in concentration 100-120 ng/mg which is an active substance of gene-therapeutic drug Neovasculgen®.
Study: NCT05203354

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Narrowband Ultraviolet B
Description: patients will exposed to sessions of NB-UVB phototherapy twice weekly for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acitretin
Description: patients will received acitretin in dose 0.5-1 mg/kg daily for 3 months
Study: NCT00454766

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Survey of two educational brochures with approximately the same information, but which vary in their health literacy (readability) level.
Study: NCT00645541

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary Reverse Mapping
Description: Lymphazurin, isosulfan blue dye, injected into arm then a standard axillary lymph node surgery to remove any blue dyed lymph nodes found (lymph nodes that have traveled down the drainage pathways).
Study: NCT05632445

Intervention type: DRUG
Group type: OTHER
Intervention: Apixaban vs. DAPT
Description: Apixaban vs DAPT after LAAO

Intervention type: DRUG
Group type: OTHER
Intervention: Apixaban vs. DAPT
Description: Apixaban vs DAPT after LAAO
Study: NCT02019043

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Syphilis testing with routine HIV bloodwork
Description: The intervention condition will be implemented as standing orders for syphilis serology whenever patients undergo their standard battery of follow-up bloodwork, i.e., when there is an order for HIV viral load or CD4 cell count. It is standard practice for HIV patients to undergo such tests every 3-6 months. We anticipate that the change in practice will be straightforward, involving minimal training of clinic staff. Team members who are physicians at these clinics will guide the specific approach that will be appropriate and sustainable for their setting. Options are quite simple. They include pre-printing a checkmark for 'syphilis serology' onto existing pre-printed requisitions for routine bloodwork; addition of the serology request form to the routine blood work package; or programming 'syphilis serology' into existing computerized routine order sets.
Study: NCT03446729

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guided Self-Help Behavioral Weight Loss
Description: Guided self-help Behavioral Weight Loss including 7 visits over 12 weeks. The treatment content includes self-monitoring, healthy eating, stimulus control, increasing physical activity, reducing sedentary activity, planning ahead for high-risk situations, and relapse prevention. The 7 visits are conducted with a behavioral coach to give participants educational materials and to promote accountability. The behavioral coach's role in the gshBWL program is to measure participant weight, collect self-monitoring booklets, clarify materials, and problem-solve barriers to adherence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Self-Help Behavioral Weight Loss
Description: Guided self-help Behavioral Weight Loss including 7 visits over 12 weeks. The treatment content includes self-monitoring, healthy eating, stimulus control, increasing physical activity, reducing sedentary activity, planning ahead for high-risk situations, and relapse prevention. The 7 visits are conducted with a behavioral coach to give participants educational materials and to promote accountability. The behavioral coach's role in the gshBWL program is to measure participant weight, collect self-monitoring booklets, clarify materials, and problem-solve barriers to adherence.
Study: NCT02811185

Intervention type: DRUG
Group type: OTHER
Intervention: [F-18]-Fludeoxyglucose
Description: Radiopharmaceutical imaging agent

Intervention type: DRUG
Group type: OTHER
Intervention: [F-18]-Fludeoxyglucose
Description: Radiopharmaceutical imaging agent
Study: NCT05695625

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia + bilateral erector spine plane block
Description: Intraoperative period: Spinal anesthesia was administered with 0.5% bupivacaine and fentanyl 12.5mcg at the level of L4-5 interspace in the sitting position. At the end of the surgery, patients were given a sitting position with the help of 2 people for USG-guided ESPB. The high-frequency linear USG probe was placed in the midline at T12 level, after the spinous process visualized, the transverse process was visualized by moving probe 3-4cm laterally. After confirming the location of the needle tip with 1-2ml hydrodissection, 10 ml bupivacaine + 10 ml salin was applied both right and left sides.~Postoperative period: If patients' VAS value \>4, 75mg diclofenac intramuscular was administered. After 30 mins if patients' VAS values \>4, 1000mg paracetamol intravenously was administered.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia
Description: Intraoperative period: Spinal anesthesia was administered with 0.5% bupivacaine and fentanyl 12.5mcg at the level of L4-5 interspace in the sitting position.~Postoperative period: If patients' VAS value \>4, 75mg diclofenac intramuscular was administered. After 30 mins if patients' VAS values \>4, 1000mg paracetamol intravenously was administered.
Study: NCT03711851

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help Acceptance and commitment therapy (Web-based)
Description: 9 week program with minimal contact with therapist (predominantly self-help)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-help Acceptance and commitment therapy (bibliotherapy)
Description: 9 week program with contact with therapist (predominantly self-help)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-help Education pamphlets on pain (active control group)
Description: 9 week program with contact with therapist (predominantly self-help)
Study: NCT02736305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Once a day for 21 days in a 28 days cycle
Study: NCT02261051

Intervention type: OTHER
Intervention: Standard of care
Description: Patients will be cared for using current standard of care preceding the design and implementation of the LCCM model of care.
Study: NCT01203748

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PVI + Lines ablation
Description: Pulmonary vein antrum isolation with additional linear ablation (mitral line and roof line)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI
Description: Pulmonary vein antrum isolation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PVI + CFE ablation
Description: Pulmonary vein antrum isolation with additional complex fractionated electrogram ablation
Study: NCT01054846

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bicycle helmet from Bell Sports Inc.
Description: As described under the respective arm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bicycle helmet education only
Description: As described under the respective arm
Study: NCT02325167

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EBT
Description: participants assigned to the intervention arm will receive 2 manualised therapy sessions with focus on mindfulness and activating resources delivered by trained therapists at the Clinic of Palliative Care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: treatment-as-usual
Description: participants assigned to the treatment-as-usual arm will receive 2 supportive sessions delivered by trained therapists at the Clinic of Palliative Care